Table 2.

Change in hepatic steatosis (CAP score) and fibrosis (LSM)

	Placebo (n = 37)			Empagliflozin (n = 35)			Pioglitazone (n = 34)
	Baseline	Week 24	p	Baseline	Week 24	p	Baseline	Week 24	p
CAP score (dB/m)	313.14 ± 30.40	296.73 ± 40.13	< 0.001	317.37 ± 28.46	287.80 ± 31.14	< 0.001	308.76 ± 30.59	280.91 ± 34.52	< 0.001
LSM (KPa)	7.49 ± 2.65	7.17 ± 2.67	0.27	6.83 ± 2.44	6.01 ± 1.65	0.005	6.48 ± 1.67	6.42 ± 2.14	0.80

Data are mean ± SD. p value within each group that compared baseline data with end of trial results; statistically significant p values (p < 0.05) are in bold